Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Yasser Ged"'
Autor:
Rajan Singh, Anand K. Thotakura, Suresh Alati, Alla Lisok, Zirui Jiang, Vanessa F. Merino, Il Minn, Santosh Yadav, Mark C. Markowski, Yasser Ged, Christian P. Pavlovich, Nirmish Singla, Lilja B. Solnes, Michael A. Gorin, Martin G. Pomper, Steven P. Rowe, Sangeeta Ray Banerjee
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
IntroductionRenal cell carcinoma (RCC) represents cancer originating from the renal epithelium and accounts for > 90% of cancers in the kidney. Prostate-specific membrane antigen (PSMA) is overexpressed in tumor-associated neovascular endothelial cel
Externí odkaz:
https://doaj.org/article/0b43bcfa255e43f883bee194298d2a44
Publikováno v:
Urology Case Reports, Vol 56, Iss , Pp 102824- (2024)
We present the case of a 64-year-old patient with metastatic renal cell carcinoma, who experienced disease progression despite undergoing multiple lines of systemic therapy, including immune checkpoint inhibitors (ICI). Two months after stereotactic
Externí odkaz:
https://doaj.org/article/01b6feb1a1a7475590ca17beab5a395f
Autor:
Evan J Lipson, Jarushka Naidoo, Julie Brahmer, Ludmila Danilova, Elizabeth M Jaffee, Won Jin Ho, Mark Yarchoan, Maximilian F Konig, Yasser Ged, Jean Hoffman-Censits, Jennifer Durham, Laura Cappelli, Sanjay Bansal, Aanika Balaji, Rajat Mohindra, Stephanie L Alden, Tanguy Y Seiwert, Chester J Kao, Soren Charmsaz, Madalena Brancati, Howard L Li, Kabeer Munjal, Hua-Ling Tsai, Alexei Hernandez, Nicole Gross, Erin M Coyne, Sarah M Shin, Brian Christmas, Christopher Thoburn, Marina Barretti, Rachel Garonce-Hediger, Laura Tang, G Scott Chandler
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/9ecf458f7da7428ea7c6e82123a0c044
Publikováno v:
Frontiers in Oncology, Vol 12 (2022)
The use of immune-checkpoint inhibitor (ICI) therapy has significantly improved patient outcomes in a wide variety of cancers and has become a cornerstone in the treatment of renal cell carcinoma. However, ICI treatment has the potential to cause a v
Externí odkaz:
https://doaj.org/article/5f72688f580c4ee5b2b5e243a58663ae
Autor:
A. Ari Hakimi, Kyrollis Attalla, Renzo G. DiNatale, Irina Ostrovnaya, Jessica Flynn, Kyle A. Blum, Yasser Ged, Douglas Hoen, Sviatoslav M. Kendall, Ed Reznik, Anita Bowman, Jason Hwee, Christopher J. Fong, Fengshen Kuo, Martin H. Voss, Timothy A. Chan, Robert J. Motzer
Publikováno v:
Nature Communications, Vol 11, Iss 1, Pp 1-11 (2020)
The clinical benefit from immunotherapy response in patients with mutations of genes forming the chromatin remodelling complex PBAF remains controversial. Here the authors show that PBAF complex mutations are not associated with favourable response i
Externí odkaz:
https://doaj.org/article/655ac0280dd44b29884b0203c1be1bd4
Autor:
Yasser Ged, Ruby Gupta, Cihan Duzgol, Andrea Knezevic, Natalie Shapnik, Ritesh Kotecha, Martin H. Voss, Darren R. Feldman, Oguz Akin, Sujata Patil, Robert J. Motzer, Brian I. Rini, Chung-Han Lee
Publikováno v:
BMC Urology, Vol 20, Iss 1, Pp 1-8 (2020)
Abstract Background Several phase 3 studies reported positive results for combinations of Immune-Oncology (IO) and Vascular Endothelial Growth Factor (VEGF) targeted therapies in patients with metastatic clear cell Renal Cell Carcinoma (ccRCC). Howev
Externí odkaz:
https://doaj.org/article/bcef04eeb40d49a8b5def4d483894b30
Publikováno v:
Case Reports in Urology, Vol 2022 (2022)
Renal cell carcinoma (RCC) is considered to be the deadliest urologic cancer with high rates of metastasis and recurrence after nephrectomy. RCC can metastasize to nearly any organ but most commonly metastasizes to the liver, lung, brain, and bone. T
Externí odkaz:
https://doaj.org/article/0af50991839d4daea743cbba7bf5eb4f
Autor:
Yasser Ged, Martin H. Voss
Publikováno v:
Therapeutic Advances in Medical Oncology, Vol 13 (2021)
The treatment of metastatic renal cell carcinoma has significantly evolved in recent years, particularly with the advent of novel immune checkpoint inhibitors (ICI). Despite the striking benefits observed on a population level, outcomes vary and some
Externí odkaz:
https://doaj.org/article/85f04da038e547b387181e4738d986d2
Autor:
Andrea Knezevic, Sujata Patil, Martin H Voss, Yasser Ged, Joshua L Chaim, Renzo G DiNatale, Ritesh R Kotecha, Maria I Carlo, Chung-Han Lee, Ashley Foster, Darren R Feldman, Min Yuen Teo, Gopakumar Iyer, Timothy Chan, Robert J Motzer, A Ari Hakimi
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 8, Iss 1 (2020)
Background Loss-of-function alterations in DNA damage repair (DDR) genes are associated with human tumorigenesis and may determine benefit from immune-oncology (I/O) agents as shown in colon cancer. However, biologic significance and relevance to I/O
Externí odkaz:
https://doaj.org/article/256aee4f74274772a16f55b728dc15b9
Autor:
Yasser Ged, Alejandro Sanchez, Sujata Patil, Andrea Knezevic, Emily Stein, Stacey Petruzella, Kate Weiss, Cihan Duzgol, Joshua Chaim, Oguz Akin, Marina Mourtzakis, Michael T. Paris, Jessica Scott, Fengshen Kuo, Ritesh Kotecha, A. Ari Hakimi, Chung-Han Lee, Robert J. Motzer, Martin H. Voss, Helena Furberg
Publikováno v:
Clinical Cancer Research. 28:5180-5189
Purpose: High body mass index (BMI) may lead to improved immune-checkpoint blockade (ICB) outcomes in metastatic clear cell renal cell carcinoma (mccRCC). However, BMI is a crude body size measure. We investigated BMI and radiographically assessed bo
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::10c4b87eed50610e472473dbeefa2545
https://doi.org/10.1158/1078-0432.ccr-22-1389
https://doi.org/10.1158/1078-0432.ccr-22-1389